Nippon India Taiwan Equity Fund- Direct Plan- Growth Option vs HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan
A side-by-side comparison of returns, cost, size and risk. Both funds sit in the same category, so these figures are directly comparable.
NAV as of 17 Aug 2026. Returns over 1 year are annualised. Past performance does not indicate future returns, and this comparison is not a recommendation.
| Metric | Nippon India Taiwan Equity Fund | HDFC Pharma and Healthcare Fund |
|---|---|---|
| Category | Sectoral/ Thematic | Sectoral/ Thematic |
| Fund house | Nippon India Mutual Fund | HDFC Mutual Fund |
| NAV | ₹37.815 | ₹22.204 |
| 1Y return | +121.55% | +26.61% |
| 3Y return | +61.34% | +30.17% |
| 5Y return | — | — |
| AUM | ₹1,128 Cr | ₹3,311 Cr |
| Expense ratio | 1.07% | 1.03% |
| Risk | Very High | Very High |
Highlighting marks the higher return or lower cost on rows where both funds have data. It is arithmetic, not advice — a cheaper or higher-returning fund is not automatically the better choice for you.